

Supplementary Table 1. Comparison of the percentage of patients within the target Hb range between the two groups during the efficacy evaluation period

Variable	Intention-to-treat population			Per-protocol population		
	DA (n = 20)	CERA (n = 20)	p-value	DA (n = 16)	CERA (n = 15)	p-value
Mean % frequency						
Within target Hb range	48.61 ± 27.15	49.07 ± 24.57	0.96	43.75 ± 24.25	42.22 ± 17.67	0.84
Exceed target Hb range	26.39 ± 31.86	30.56 ± 28.73	0.68	28.12 ± 33.18	36.67 ± 27.60	0.44
Less than target Hb range	25.00 ± 26.97	20.37 ± 29.46	0.63	28.12 ± 27.02	21.11 ± 30.52	0.50

Data are expressed as mean ± standard deviation.

CERA, continuous erythropoietin receptor activator; DA, darbepoetin alfa; Hb, hemoglobin.